Evaluation of Xpert MTB/RIF assay accuracy for diagnosing TB and detecting rifampin resistance in patients with very low bacterial loads results: a retrospective study in Hunan, China

There is widespread use of Xpert MTB/RIF for tuberculosis (TB) diagnosis and rifampin resistance (RIF-R) detection. Despite this, concerns have been raised about false-positive results, which are more prevalent in patients with very low bacterial loads. We performed a retrospective analysis of 717 patients at Hunan Chest Hospital from January 2022 to January 2023, all of whom had Xpert MTB/RIF results indicating very low bacterial loads. The accuracy of Xpert in diagnosing TB was evaluated against a composite reference standard (CRS), which classified cases via symptom, liquid culture, imaging assessments, immunological tests, and therapeutic response. In addition, rifampicin resistance was adjudicated using a composite reference standard of pDST and rpoB sequencing, with pDST as the primary reference for Xpert MTB/RIF results and sequencing used to resolve discrepancies. Of 717 patients with Xpert detected very low bacterial loads, 175 (24.4%) yielded positive cultures, while 16 cases identified as non-tuberculous mycobacteria (NTM). The positive predictive value (PPV) of Xpert for bacteriologically confirmed TB was 90.8% (159/175). For 542 culture-negative patients, Xpert’s PPV was 81.7% (443/542) in clinically diagnosed TB (80.4% pulmonary TB, 88.9% extrapulmonary TB). In 121 patients with pDST, Xpert for RIF-R had 68.4% sensitivity (13/19), 88.2% specificity (90/102), respectively. Among the 6 patients who were RIF-R by pDST but rifampin susceptible by Xpert, four cases harbored mutations inside the 81-bp Rifampicin Resistance-Determining Region (RRDR) region of rpoB. Xpert demonstrates good performance in diagnosing TB among the patients with results showing very low bacterial loads, especially in the culture-positive group and extrapulmonary tuberculosis group. However, its performance in detecting rifampicin resistance is not reliable. Our findings emphasize that Xpert results showing very low bacterial loads should be confirmed when diagnosing rifampin resistance tuberculosis.

Authors

Institutions

Publication Details

Journal
BMC Infectious Diseases
Published
2026-03-02
DOI
https://doi.org/10.1186/s12879-026-12933-3
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of Xpert MTB/RIF assay accuracy for diagnosing TB and detecting rifampin resistance in patients with very low bacterial loads results: a retrospective study in Hunan, China

Hua Bai, Daofang Gong, Jingwei Guo, Yunhong Tan et al.
BMC Infectious Diseases
Tuberculosis Research and Epidemiology
article

Evaluation of Xpert MTB/RIF assay accuracy for diagnosing TB and detecting rifampin resistance in patients with very low bacterial loads results: a retrospective study in Hunan, China

Hua Bai, Daofang Gong, Jingwei Guo, Yunhong Tan, Jue Wang, Hengzhong Yi, Xinyun Tan, Yi Liu, Xuan Zeng, Yi Wu, Peilei Hu
article en

Abstract

There is widespread use of Xpert MTB/RIF for tuberculosis (TB) diagnosis and rifampin resistance (RIF-R) detection. Despite this, concerns have been raised about false-positive results, which are more prevalent in patients with very low bacterial loads. We performed a retrospective analysis of 717 patients at Hunan Chest Hospital from January 2022 to January 2023, all of whom had Xpert MTB/RIF results indicating very low bacterial loads. The accuracy of Xpert in diagnosing TB was evaluated against a composite reference standard (CRS), which classified cases via symptom, liquid culture, imaging assessments, immunological tests, and therapeutic response. In addition, rifampicin resistance was adjudicated using a composite reference standard of pDST and rpoB sequencing, with pDST as the primary reference for Xpert MTB/RIF results and sequencing used to resolve discrepancies. Of 717 patients with Xpert detected very low bacterial loads, 175 (24.4%) yielded positive cultures, while 16 cases identified as non-tuberculous mycobacteria (NTM). The positive predictive value (PPV) of Xpert for bacteriologically confirmed TB was 90.8% (159/175). For 542 culture-negative patients, Xpert’s PPV was 81.7% (443/542) in clinically diagnosed TB (80.4% pulmonary TB, 88.9% extrapulmonary TB). In 121 patients with pDST, Xpert for RIF-R had 68.4% sensitivity (13/19), 88.2% specificity (90/102), respectively. Among the 6 patients who were RIF-R by pDST but rifampin susceptible by Xpert, four cases harbored mutations inside the 81-bp Rifampicin Resistance-Determining Region (RRDR) region of rpoB. Xpert demonstrates good performance in diagnosing TB among the patients with results showing very low bacterial loads, especially in the culture-positive group and extrapulmonary tuberculosis group. However, its performance in detecting rifampicin resistance is not reliable. Our findings emphasize that Xpert results showing very low bacterial loads should be confirmed when diagnosing rifampin resistance tuberculosis.

BMC Infectious Diseases
Central South University (CN), Hunan Normal University (CN), Hunan Province Chest Hospital (CN)
Good health and well-being
Openalex Percentile: Top 38%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.